Development made in breakdown of a Meningitis B vaccine component
Scientists from the Health Protection Agency (HPA) are a step closer to ensuring the stability of a component of a vaccine that may one day be used to protect against Meningitis B. The research is published today (Tuesday) in Vaccine. (Source: Health Protection Agency)
Dr. David Boger on ECT
Dr. David Boger presented to the U.S. Food and Drug Administration Neurological Devices Panel examining the reclassification of electroconvulsive therapy (ECT) devices on January 27, 2011. These are his remarks as published in the public record of the meeting.
Good afternoon. My name is Dr. David Boger. I#8217;m a board certified adult psychiatrist in private practice in New York City.
I come to you today both as a physician who supports the use of ECT in carefully selected patient populations and as a patient myself who has undergone extensive electroconvulsive therapy. I refer you to my personal article I wrote entitled, #8220;Shocking the Shrink: A Psychiatrist Undergoes ECT.#8221; I#8217;ve experienced episodic depressions characterized by sleep and appetite disturbance, impaired...
